Xceleron Accelerates Early Drug Development

Xceleron combines ultra-sensitive analysis with knowledge of drug ADME/PK in humans. Our clients use this approach in translational medicine and to enable traditional ADME studies with difficult compounds and in sensitive populations.

We have developed a portfolio of services enabling candidate selection and early development decisions before and during clinical Phase I studies and in PII/III.  We conduct Phase 0/Microdosing, intravenous pharmacokinetics, metabolite profiling and mass balance investigations in humans.

Xceleron's clients have access to the world’s most experienced team in this field:

• Unmatched global analytical capacity
• Dedicated Quality Assurance professionals
  
• Scientists with experience solving drug development problems
• Tested collaborator network necessary to accelerate pharmaceutical and biotechnology client drug development